Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage

Vaccine

Volumn 24, Issue 40-41, 2006, Pages 6376-6391

  Yu, Qigui ^a,b   Jones, Brad ^b   Hu, Ningjie ^a,c   Chang, Hong ^d   Ahmad, Sidrah ^b   Liu, Jun ^b   Parrington, Mark ^e   Ostrowski, Mario ^b,f  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Sanofi Pasteur   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

ALVAC; Dendritic cell; Monocyte; Myeloid cell; Vaccinia; Virus

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW CULTURE; CANARYPOX VIRUS; CELL LINEAGE; CELL MATURATION; DENDRITIC CELL; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; VIRUS GENE; VIRUS INFECTION;

ANTIGENS, CD14; CANARYPOX VIRUS; CD40 LIGAND; CELL LINEAGE; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; MONOCYTES; TIME FACTORS; VACCINIA VIRUS;

EID: 33748465749     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.011     Document Type: Article

References (51)

1. Moss B. Vaccinia and other poxvirus expression vectors. Curr Opin Biotechnol 3 5 (1992) 518-522
2. Moss B., Fuerst T.R., Flexner C., and Hugin A. Roles of vaccinia virus in the development of new vaccines. Vaccine 6 2 (1988) 161-163
3. Moss B., and Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 5 (1987) 305-324
4. Bostock C.J. Viruses as vectors. Vet Microbiol 23 1-4 (1990) 55-71
5. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 5 (1996) 428-434
6. McFadden G. Poxvirus tropism. Nat Rev Microbiol 3 3 (2005) 201-213
7. Krugman S., and Katz S.L. Smallpox vaccination. N Engl J Med 281 22 (1969) 1241-1242
8. Welter J., Taylor J., Tartaglia J., Paoletti E., and Stephensen C.B. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol 74 14 (2000) 6358-6367
9. Tartaglia J., Jarrett O., Neil J.C., Desmettre P., and Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67 4 (1993) 2370-2375
10. Salmon-Ceron D., Excler J.L., Finkielsztejn L., Autran B., Gluckman J.C., Sicard D., et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 15 7 (1999) 633-645
11. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23 19 (2005) 2522-2529
12. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 1 (1992) 217-232
13. Marovich M.A., Mascola J.R., Eller M.A., Louder M.K., Caudrelier P.A., El-Habib R., et al. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J Infect Dis 186 9 (2002) 1242-1252
14. Marovich M.A. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev Vaccines 3 4 Suppl. (2004) S99-S104
15. Tartaglia J., Cox W.I., Taylor J., Perkus M., Riviere M., Meignier B., et al. Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 8 8 (1992) 1445-1447
16. Cox W.I., Tartaglia J., and Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195 2 (1993) 845-850
17. Abimiku A.G., Franchini G., Tartaglia J., Aldrich K., Myagkikh M., Markham P.D., et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1 4 (1995) 321-329
18. Andersson S., Makitalo B., Thorstensson R., Franchini G., Tartaglia J., Limbach K., et al. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis 174 5 (1996) 977-985
19. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180 3 (1999) 843-846
20. Ghose A., Iakhnina E., Spaner D., Tartaglia J., and Berinstein N.L. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector. Hum Gene Ther 11 9 (2000) 1289-1301
21. Konishi E., Kurane I., Mason P.W., Shope R.E., Kanesa-Thasan N., Smucny J.J., et al. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 16 8 (1998) 842-849
22. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 74 23 (2000) 11329-11338
23. Chahroudi A., Chavan R., Koyzr N., Waller E.K., Silvestri G., and Feinberg M.B. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79 16 (2005) 10397-10407
24. Sanchez-Puig J.M., Sanchez L., Roy G., and Blasco R. Susceptibility of different leukocyte cell types to vaccinia virus infection. Virol J 1 1 (2004) 10
25. + T cells by infected dendritic cells in vivo. Nat Immunol 3 3 (2002) 265-271
26. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 4 (1994) 1109-1118
27. + T cell responses. J Immunol 165 11 (2000) 6133-6141
28. + T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 170 4 (2003) 1797-1805
29. Ercolani L., Florence B., Denaro M., and Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 263 30 (1988) 15335-15341
30. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69 (2000) 531-569
31. Brinkman-Van der Linden E.C., Angata T., Reynolds S.A., Powell L.D., Hedrick S.M., and Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol 23 12 (2003) 4199-4206
32. van Lochem E.G., van der Velden V.H., Wind H.K., te Marvelde J.G., Westerdaal N.A., and van Dongen J.J. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 60 1 (2004) 1-13
33. Skinner N.A., MacIsaac C.M., Hamilton J.A., and Visvanathan K. Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens. Clin Exp Immunol 141 2 (2005) 270-278
34. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13 6 (1995) 539-549
35. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 163 12 (1999) 6762-6768
36. Jenne L., Hauser C., Arrighi J.F., Saurat J.H., and Hugin A.W. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther 7 18 (2000) 1575-1583
37. Broder C.C., Kennedy P.E., Michaels F., and Berger E.A. Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors. Gene 142 2 (1994) 167-174
38. de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22 5-6 (2004) 704-713
39. CDC, US Department of Health and Human Services. Vaccinia (smallpox) vaccine: recommendations of the ACIP, 2001. CDC; MMWR, Atlanta, GA, 2001.
40. Kinloch-de Loes S. Role of therapeutic vaccines in the control of HIV-1. J Antimicrob Chemother 53 4 (2004) 562-566
41. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101
42. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182 2 (1995) 389-400
43. Reddy A., Sapp M., Feldman M., Subklewe M., and Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90 9 (1997) 3640-3646
44. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 4 (1998) 1947-1953
45. Thurner B., Roder C., Dieckmann D., Heuer M., Kruse M., Glaser A., et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223 1 (1999) 1-15
46. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 11 (1999) 1669-1678
47. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61 23 (2001) 8513-8519
48. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104 2 (1999) 173-180
49. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., and Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193 2 (2001) 233-238
50. Freeman S.D., Kelm S., Barber E.K., and Crocker P.R. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 8 (1995) 2005-2012
51. Imamura R., Miyamoto T., Yoshimoto G., Kamezaki K., Ishikawa F., Henzan H., et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol 175 4 (2005) 2647-2654